In vitro antitumor activity of rebeccamycin analog (NSC 655649) against pediatric solid tumors

Steven D Weitman, Rodney Moore, Hector Barrera, Nai Kong Cheung, Elzbieta Izbicka, Daniel D. Von Hoff

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Purpose: This study determined the in vitro antitumor activity of a rebeccamycin analog (NSC 655649) using tetrazolium/formazan (MTT) and clonogenic assays against established pediatric cell lines and solid tumor specimens obtained from children. Materials and Methods: Tumor cells from 14 established cell lines and 20 patient specimens were exposed in vitro for 1 hour to NSC 655649 at concentrations ranging from 0.015 to 15.0 μM. The cytotoxicity (IC50) of this agent against established cell lines was determined using both the MTT (cytotoxic) and clonogenic/soft agar cloning (cytostatic) assays. Tumor specimens from children undergoing biopsy or surgical resection were also evaluated in vitro against NSC 655649 using the clonogenic assay. For studies using patient specimens, antitumor activity was measured by comparing the number of tumor colonies from NSC 655649-treated cells with those from solvent-treated controls. Results: These studies showed that the mean IC50s using the MTT and clonogenic assays using established solid tumor cell lines were 0.94 and 0.51 μM, respectively. In general, for cell lines tested using both types of assays, the clonogenic assay resulted in a smaller IC50. The overall in vitro responses (≤50% survival compared to controls) using patient tumor specimens and the clonogenic assay were 35% (1.5 μM), 60% (7.5 μM), and 80% (15.0 μM). Of the 9 patients with neuroblastoma, responses to NSC 655649 were seen in 33% (1.5 μM), 58% (7.5 μM), and 92% (15.0 μM) of the specimens. Prior chemotherapy did not appear to adversely affect in vitro responses. Conclusions: NSC 655649 appears to have broad antitumor activity in vitro against pediatric malignancies at drug concentrations achieved during adult phase I clinical trials. These studies support the further development of NSC 655649 for solid tumors in children.

Original languageEnglish (US)
Pages (from-to)136-139
Number of pages4
JournalJournal of Pediatric Hematology/Oncology
Volume20
Issue number2
DOIs
StatePublished - 1998

Fingerprint

becatecarin
Pediatrics
Neoplasms
Tumor Cell Line
Cell Line
Inhibitory Concentration 50
Clinical Trials, Phase I
Cytostatic Agents
In Vitro Techniques
rebeccamycin
Neuroblastoma
Agar
Organism Cloning

Keywords

  • Cancer
  • Cytotoxicity
  • Pediatric
  • Soft agar cloning

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Cite this

In vitro antitumor activity of rebeccamycin analog (NSC 655649) against pediatric solid tumors. / Weitman, Steven D; Moore, Rodney; Barrera, Hector; Cheung, Nai Kong; Izbicka, Elzbieta; Von Hoff, Daniel D.

In: Journal of Pediatric Hematology/Oncology, Vol. 20, No. 2, 1998, p. 136-139.

Research output: Contribution to journalArticle

Weitman, Steven D ; Moore, Rodney ; Barrera, Hector ; Cheung, Nai Kong ; Izbicka, Elzbieta ; Von Hoff, Daniel D. / In vitro antitumor activity of rebeccamycin analog (NSC 655649) against pediatric solid tumors. In: Journal of Pediatric Hematology/Oncology. 1998 ; Vol. 20, No. 2. pp. 136-139.
@article{e7f2b2d0a90f4adf96d55e0cb1ea7cfc,
title = "In vitro antitumor activity of rebeccamycin analog (NSC 655649) against pediatric solid tumors",
abstract = "Purpose: This study determined the in vitro antitumor activity of a rebeccamycin analog (NSC 655649) using tetrazolium/formazan (MTT) and clonogenic assays against established pediatric cell lines and solid tumor specimens obtained from children. Materials and Methods: Tumor cells from 14 established cell lines and 20 patient specimens were exposed in vitro for 1 hour to NSC 655649 at concentrations ranging from 0.015 to 15.0 μM. The cytotoxicity (IC50) of this agent against established cell lines was determined using both the MTT (cytotoxic) and clonogenic/soft agar cloning (cytostatic) assays. Tumor specimens from children undergoing biopsy or surgical resection were also evaluated in vitro against NSC 655649 using the clonogenic assay. For studies using patient specimens, antitumor activity was measured by comparing the number of tumor colonies from NSC 655649-treated cells with those from solvent-treated controls. Results: These studies showed that the mean IC50s using the MTT and clonogenic assays using established solid tumor cell lines were 0.94 and 0.51 μM, respectively. In general, for cell lines tested using both types of assays, the clonogenic assay resulted in a smaller IC50. The overall in vitro responses (≤50{\%} survival compared to controls) using patient tumor specimens and the clonogenic assay were 35{\%} (1.5 μM), 60{\%} (7.5 μM), and 80{\%} (15.0 μM). Of the 9 patients with neuroblastoma, responses to NSC 655649 were seen in 33{\%} (1.5 μM), 58{\%} (7.5 μM), and 92{\%} (15.0 μM) of the specimens. Prior chemotherapy did not appear to adversely affect in vitro responses. Conclusions: NSC 655649 appears to have broad antitumor activity in vitro against pediatric malignancies at drug concentrations achieved during adult phase I clinical trials. These studies support the further development of NSC 655649 for solid tumors in children.",
keywords = "Cancer, Cytotoxicity, Pediatric, Soft agar cloning",
author = "Weitman, {Steven D} and Rodney Moore and Hector Barrera and Cheung, {Nai Kong} and Elzbieta Izbicka and {Von Hoff}, {Daniel D.}",
year = "1998",
doi = "10.1097/00043426-199803000-00009",
language = "English (US)",
volume = "20",
pages = "136--139",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - In vitro antitumor activity of rebeccamycin analog (NSC 655649) against pediatric solid tumors

AU - Weitman, Steven D

AU - Moore, Rodney

AU - Barrera, Hector

AU - Cheung, Nai Kong

AU - Izbicka, Elzbieta

AU - Von Hoff, Daniel D.

PY - 1998

Y1 - 1998

N2 - Purpose: This study determined the in vitro antitumor activity of a rebeccamycin analog (NSC 655649) using tetrazolium/formazan (MTT) and clonogenic assays against established pediatric cell lines and solid tumor specimens obtained from children. Materials and Methods: Tumor cells from 14 established cell lines and 20 patient specimens were exposed in vitro for 1 hour to NSC 655649 at concentrations ranging from 0.015 to 15.0 μM. The cytotoxicity (IC50) of this agent against established cell lines was determined using both the MTT (cytotoxic) and clonogenic/soft agar cloning (cytostatic) assays. Tumor specimens from children undergoing biopsy or surgical resection were also evaluated in vitro against NSC 655649 using the clonogenic assay. For studies using patient specimens, antitumor activity was measured by comparing the number of tumor colonies from NSC 655649-treated cells with those from solvent-treated controls. Results: These studies showed that the mean IC50s using the MTT and clonogenic assays using established solid tumor cell lines were 0.94 and 0.51 μM, respectively. In general, for cell lines tested using both types of assays, the clonogenic assay resulted in a smaller IC50. The overall in vitro responses (≤50% survival compared to controls) using patient tumor specimens and the clonogenic assay were 35% (1.5 μM), 60% (7.5 μM), and 80% (15.0 μM). Of the 9 patients with neuroblastoma, responses to NSC 655649 were seen in 33% (1.5 μM), 58% (7.5 μM), and 92% (15.0 μM) of the specimens. Prior chemotherapy did not appear to adversely affect in vitro responses. Conclusions: NSC 655649 appears to have broad antitumor activity in vitro against pediatric malignancies at drug concentrations achieved during adult phase I clinical trials. These studies support the further development of NSC 655649 for solid tumors in children.

AB - Purpose: This study determined the in vitro antitumor activity of a rebeccamycin analog (NSC 655649) using tetrazolium/formazan (MTT) and clonogenic assays against established pediatric cell lines and solid tumor specimens obtained from children. Materials and Methods: Tumor cells from 14 established cell lines and 20 patient specimens were exposed in vitro for 1 hour to NSC 655649 at concentrations ranging from 0.015 to 15.0 μM. The cytotoxicity (IC50) of this agent against established cell lines was determined using both the MTT (cytotoxic) and clonogenic/soft agar cloning (cytostatic) assays. Tumor specimens from children undergoing biopsy or surgical resection were also evaluated in vitro against NSC 655649 using the clonogenic assay. For studies using patient specimens, antitumor activity was measured by comparing the number of tumor colonies from NSC 655649-treated cells with those from solvent-treated controls. Results: These studies showed that the mean IC50s using the MTT and clonogenic assays using established solid tumor cell lines were 0.94 and 0.51 μM, respectively. In general, for cell lines tested using both types of assays, the clonogenic assay resulted in a smaller IC50. The overall in vitro responses (≤50% survival compared to controls) using patient tumor specimens and the clonogenic assay were 35% (1.5 μM), 60% (7.5 μM), and 80% (15.0 μM). Of the 9 patients with neuroblastoma, responses to NSC 655649 were seen in 33% (1.5 μM), 58% (7.5 μM), and 92% (15.0 μM) of the specimens. Prior chemotherapy did not appear to adversely affect in vitro responses. Conclusions: NSC 655649 appears to have broad antitumor activity in vitro against pediatric malignancies at drug concentrations achieved during adult phase I clinical trials. These studies support the further development of NSC 655649 for solid tumors in children.

KW - Cancer

KW - Cytotoxicity

KW - Pediatric

KW - Soft agar cloning

UR - http://www.scopus.com/inward/record.url?scp=0031896616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031896616&partnerID=8YFLogxK

U2 - 10.1097/00043426-199803000-00009

DO - 10.1097/00043426-199803000-00009

M3 - Article

C2 - 9544164

AN - SCOPUS:0031896616

VL - 20

SP - 136

EP - 139

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 2

ER -